Fill Out Your Profile to share more about you. Learn more...

FDA Approves Orserdu for ER+ MBC (oral SERD)

Options
moderators
moderators Posts: 7,928

FDA Approves Orserdu for Metastatic, Estrogen Receptor-Positive Breast Cancer
Jan 27, 2023

The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation. Read more....